About Solentim
Solentim is a company based in Wimborne Minster (United Kingdom) founded in 2010 was acquired by Advanced Instruments in August 2021. The company has 47 employees as of June 30, 2021. Solentim offers products and services including OsmoTECH XT, OsmoPRO MAX, Artel MVS, and GloCyte. Solentim operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Wimborne Minster, United Kingdom
- Employees 47 as on 30 Jun, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Advanced Instruments Ltd.
- Date of Incorporation 15 Jun, 2010
- Jurisdiction WIMBORNE, DORSET, ENGLAND
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$895.3 K (USD), Grant
Jun 01, 2019
-
Investors
Advanced Instruments
& 1 more
-
Employee Count
47
as on Jun 30, 2021
-
Acquired by
Advanced Instruments
(Aug 05, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Solentim
Solentim offers a comprehensive portfolio of products and services, including OsmoTECH XT, OsmoPRO MAX, Artel MVS, and GloCyte.
Single-sample micro-osmometer for bioprocessing measurements
Automated osmometer for clinical sample analysis
Multichannel system for liquid handling accuracy
Automated counter for CSF cell analysis in diagnostics
Funding Insights of Solentim
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $895,303
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2019 | Amount | Grant - Solentim | Valuation |
investors |
|
| Mar, 2019 | Amount | Grant - Solentim | Valuation |
investors |
|
Investors in Solentim
Solentim has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Advanced Instruments and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Manufacturer of Laboratory equipment
|
Founded Year | Domain | Location |
Investments & Acquisitions by Solentim
Financial Statements - Solentim
Solentim Comparisons
Competitors of Solentim
Solentim operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
Frequently Asked Questions about Solentim
Solentim was founded in 2010 and raised its 1st funding round 9 years after it was founded.
Solentim is headquartered in Wimborne Minster, United Kingdom. It is registered at Wimborne Minster, Dorset, United Kingdom.
As of Jun 30, 2021, the latest employee count at Solentim is 47.
Solentim was founded in 2010 and is based in Wimborne Minster, United Kingdom. Operations focus on the biotechnology sector, where cell lines are developed for biotherapeutics, including monoclonal antibodies derived from single cells. These are applied in treatments for conditions such as cancer, autoimmune diseases, and cardiovascular disorders. Services support discovery and manufacturing processes in the biopharmaceutical industry.
Solentim's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Solentim offers OsmoTECH XT, OsmoPRO MAX, Artel MVS, and GloCyte.
Solentim has 2 investors. Key investors include Advanced Instruments, and European Union.